Peter Ellmark

Peter Ellmark – born 1973, Chief Scientific Officer – holds a Ph.D. and an associate professorship in Immunotechnology at Lund University. Peter has more than 15 years experience of in developing antibodies for the immunotherapy of cancer. Employed since 2008 and member of the Management Team since 2018.